Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported that intensive glucose control prevents end-stage kidney disease (ESKD) in patients with type 2 diabetes, but uncertainty about the balance between risks and benefits exists. Here, we examine the long-term effects of intensive glucose control on risk of ESKD and other outcomes. RESEARCH DESIGN AND METHODS: Survivors, previously randomized to intensive or standard glucose control, were invited to participate in post-trial follow-up. ESKD, defined as the need for dialysis or kidney transplantation, or death due to kidney disease, was documented overall and by baseline CKD stage, along with hypoglycemic episodes, major cardiovascular events, and death from other causes. RESULTS: A total of 8,494 ADVANCE participants were followed for a median of 5.4 additional years. In-trial HbA1c differences disappeared by the first post-trial visit. The in-trial reductions in the risk of ESKD (7 vs. 20 events, hazard ratio [HR] 0.35, P = 0.02) persisted after 9.9 years of overall follow-up (29 vs. 53 events, HR 0.54, P < 0.01). These effects were greater in earlier-stage CKD (P = 0.04) and at lower baseline systolic blood pressure levels (P = 0.01). The effects of glucose lowering on the risks of death, cardiovascular death, or major cardiovascular events did not differ by levels of kidney function (P > 0.26). CONCLUSIONS: Intensive glucose control was associated with a long-term reduction in ESKD, without evidence of any increased risk of cardiovascular events or death. These benefits were greater with preserved kidney function and with well-controlled blood pressure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, there is a lag time of at least 2 years in type 2 diabetes to over 10 years in type 1 diabetes for the effects of intensive glucose control to manifest as improved eGFR outcomes (57,61,62).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [62]
In the citing paper
“Moreover, there is a lag time of at least 2 years in type 2 diabetes to over 10 years in type 1 diabetes for the effects of intensive glucose control to manifest as improved eGFR outcomes (59)(60)(61).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [61]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Post-trial follow-up of the UK Prospective Diabetes Study (UKPDS) cohort of newly diagnosed patients with type 2 diabetes (7) and the Diabetes Control and Complications Trial (DCCT) cohort of young patients with type 1 diabetes (8) showed a sustained benefit for microvascular complications, beyond the period of intens…”
BackgroundSelf-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“Despite the implementation of “best practice” standards of care for lifestyle modification, blood pressure lowering, and renin-angiotensin-aldosterone system blockade, there remains a high level of progression to ESKD for those with diabetic kidney disease (4,5).”
BackgroundSelf-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 2×
“Despite the implementation of ‘best practice’ standards of care for lifestyle modification, blood pressure lowering and renin-angiotensin-aldosterone system (RAAS) blockade, there remains a high level of progression to ESKD for those with diabetic kidney disease (4, 5).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Andrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Worldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-H., Lv, J., Garg, A. X., Knight, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61601-9 · Cited by 2,339
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Cited by
Items 201–239 of 239
Rayner, H. C., Thomas, M. E., & Milford, D. V. (2020) · Springer eBooks · doi:10.1007/978-3-030-43027-6_6
Jung, N., Mayet, W.-J., Mertens, P. R., (federführend), J. M., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50014-0
Wang, Z., & Jian, G. (2021) · Research Square · doi:10.21203/rs.3.rs-174220/v1
Hatziisaak, N. B., Hatziisaak, T., & Keller, U. (2021) · Russian Open Medical Journal · doi:10.15275/rusomj.2021.0207
“And although intensive blood glucose lowering showed a beneficial effect on avoiding end stage kidney disease in the long run [3], lowering mortality was rather achieved by disease awareness and active cardiovascular risk factor control adapting a healthy lifestyle [4].”
BackgroundHypoglycaemia among adults with Type 2 Diabetes mellitus in a Family Medicine Clinic
Sodipo, O. O., Ademolu, A. B., Odunaye-Badmus, S., Oluwatuyi, E., & Odiana, R. N. (2021) · Annals of Health Research (The Journal of the Medical and Dental Consultants Association of Nigeria OOUTH Sagamu Nigeria) · doi:10.30442/ahr.0704-02-144
Cardiovascular Disease and Diabetic Kidney Disease
Ferdinand, K. C., Nasser, S. A., & Ali, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_14
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_14
Diabetes Medications and Cardiovascular Disease Prevention
Rho, J.-S., Lee, Y.-A., Song, S.-W., & Kang, S. G. (2022) · Korean Journal of Family Practice · doi:10.21215/kjfp.2022.12.2.61
Williams, M. E., & Stanton, R. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00006-9
Caracterización de la enfermedad renal crónica subclínica en Chile
Castillo, A., & Castillo-Montes, M. (2022) · Revista Colombiana de Nefrología · doi:10.22265/acnef.9.2.585 · Cited by 4
“Las catastró cas consecuencias descritas para la ERC pueden ser prevenidas o al menos atenuadas con una detección y un tratamiento en etapas precoces, reduciendo la progresión hacia una ERCT, retardando el ingreso a programas de diálisis y atenuando el riesgo CV [12,13].”
BackgroundSecondary Diseases of the Kidney
Natale, P., Wong, M. G., Strippoli, G. F., Tunnicliffe, D. J., Cooper, T. E., & Pollock, C. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch24
Self-citationGnecco-González, S., Amaya-Montoya, M., Herrera-Parra, L. J., Vargas, J. A. H., Ramírez-García, N., Romero-Díaz, C., Acuña-Merchán, L. A., & Mendivil, C. O. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac193 · Cited by 1
Type 2 Diabetes Mellitus: Beyond the Beta Cell
Morris, N. (2016) · EMJ Diabetes · doi:10.33590/emjdiabet/10311885
Pathomechanismen der chronischen Nierenschädigung bei Diabetes und anderen Begleiterkrankungen
Ganz, M. J., Bose, K., Herzog, C., Bender, S. T., Mertens, P. R., & Scurt, F. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01020-9
Шамхалова, М. Ш., & Sukhareva, O. Y. (2023) · Diabetes Mellitus · doi:10.14341/dm13079 · Cited by 1
Prevention and management of chronic kidney disease in diabetes
Barlovič, D. P., & Groop, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00004-x
CAPÍTULO 2: CONTROL METABÓLICO EN DIFERENTES ESTADIOS DE ENFERMEDAD RENAL CRÓNICA
Cicchitti, A., Arinovich, B., Morales, E., & Argerich, I. (2024) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v58i2sup.783
The Undiscussable Importance of Glycemic Control in the Era of Organoprotective Hypoglycemic Therapy
Biryukova, Y. V. (2024) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2024-20-8-32-42
Do You Have Diabetes Mellitus?: How Diabetes and Its Treatments Are Linked to Kidney Disease
Rayner, H. C., Thomas, M. E., Dasgupta, I., Lalayiannis, A. D., & Hameed, M. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-66349-9_7
Saurajit, D., Ayonava, S., Kalyan, M., & Pathak, I. (2023) · Journal of Applied Biochemistry & Laboratory Medicine · doi:10.5005/jablm-11031-04108
Recent Advances in Blood Glucose Management for Diabetic Patients Undergoing Hemodialysis
苏, 俊. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42237
Tan, J., Lim, G. H., Tan, H. Y., Sng, G. G. R., Thumboo, J., & Mong, B. Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5236698
Wolf, G., & Mertens, P. R. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21183-6.00006-4
Recommended procedures for diabetic kidney disease
Pelikánová, T., Viklický, O., Rychlík, I., Saudek, F., Kvapil, M., Tesař, V., Zima, T., Racek, J., & Bouček, P. (2018) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2018.010
Chronic kidney disease in metabolic syndrome
Вадимовна, В. С., & Звартау, Н. Э. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6537 · Cited by 5
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Maladie rénale chronique diabétique
Gosset, C., Rigalleau, V., Esnault, V. L. M., & Foussard, N. (2025) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)46692-4 · Cited by 1
Al-Taie, A., Hafida, M., Abdulsattar, M., & Mahmoud, R. E. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00597-z · Cited by 1
Herrington, W. G., & Haynes, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00025-2
Lo, W., Wu, M., Chen, Y.-H. R., Wu, M. S., & Wong, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-110041
Gembillo, G., Visconti, L., Tranchida, V., Nardi, C., Calimeri, S., Gambuzza, M. E., Princiotto, M., Chinigò, C., Soraci, L., & Santoro, D. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i4.115058 · Cited by 2
Wu, M.-Z., Tsang, C. T., Peng, C., Huang, J., Guo, R., Tse, Y.-K., Chan, Y., Lee, C., Zhang, J.-R., Gu, W., et al. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02263-5
“Despite recent pharmacological advancements in diabetes therapy, study has shown that intensive management of hyper-glycemia only modestly lowers the risk of microvascular complications or their progression in individuals with long-term diabetes [20].”
Lin, D. S., Lo, H.-Y., & Lee, J.-K. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046125
Eurasian clinical guidelines for the diagnosis and treatment of cardiorenal syndrome (2026)
Mitkovskaya, N. P., Chazova, I. E., Sudzhaeva, O. A., Grigorenko, E., Калачик, О. В., Геннадьевна, Ш. Л., Бранковская, Е. Ю., Смолякова, М. В., Trushina, O. I., Podzolkov, V. I., et al. (2026) · Eurasian heart journal · doi:10.38109/2225-1685-2026-2-6-41
Li, Y., Zheng, Q.-A., Chen, Y.-R., (170990), C. S., Luo, J.-Y., Zheng, Z., Xue, J., Wang, Z., Chen, Y., (156158), P. L., et al. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168312
McGill, J. B., Green, J., Heerspink, H. J. L., Mann, J. F. E., Mottl, A. K., Rosenstock, J., Rossing, P. R., Vaduganathan, M., Nangaku, M., BRINKER, M. D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70949
“While the impact of HbA1c on the progression of established CKD is less well studied, the ADVANCE trial (NCT00949286) demonstrated that intensive glucose control in participants with type 2 diabetes was associated with a long-term reduction in the rate of ESKD [14].”
Meng, X., Wang, Y., Zhang, X.-Z., Wang, S., Tan, Z., Wang, K., Zhao, X., Li, M., Wang, T., Zhao, Z., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.05.009 · Cited by 1
Wolf, G., & Mertens, P. R. (2025) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_54-2
Metadata
- Authors
- Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., Mancia, G., Marre, M., Matthews, D., Neal, B., Poulter, N., Rodgers, A., Williams, B., & Zoungas, S.
- Affiliations
- The University of Sydney (AU)
- Baker Heart and Diabetes Institute (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- The Royal Melbourne Hospital (AU)
- National Health Service (GB)
- IRCCS Istituto Auxologico Italiano (IT)
- Hôpital Bichat-Claude-Bernard (FR)
- University of Oxford (GB)
- Imperial College London (GB)
- University College London (GB)
- Corresponding author
- Perkovic, Vlado
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-03-22
- Volume
- 39
- Issue
- 5
- Pages
- 694-700
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2309242694
- Semantic Scholar
- 0dde5dd296b76622b14c9be052e0e64aac7208f9
- Cited by
- 240
- References
- 19
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 19 · 2023: 23 · 2022: 28 · 2021: 27 · 2020: 23 · 2019: 21 · 2018: 37 · 2017: 24 · 2016: 11
- FWCI
- 31.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0509-10222, NF-SI-0514-10011)
- Medical Research Council (MC_PC_13090)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tight glycemic control, end-stage renal disease, type 2 diabetes, ADVANCE trial, post-trial follow-up, chronic kidney disease, HbA1c, hypoglycemia, cardiovascular events, cardiovascular mortality, blood pressure, long-term outcomes
- MeSH terms
- Aged, Antihypertensive Agents, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Drug Combinations, Female, Follow-Up Studies, Gliclazide, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Indapamide, Kidney Failure, Chronic, Male, Middle Aged, Treatment Outcome, Perindopril
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.